Constitutional polymorphisms and response to checkpoint inhibitors. Retrospective study.
Our hypothesis is that some constitutional variations in genes involved in immune responses or oncogenesis may influence the response to immunotherapy. Accumulating data are available for the role of polymorphisms of such genes in the response to the “first generation” of immunotherapies such as BCG therapy (Chiong, 2011; Decobert, 2006) or interleukin (Eto, 2013; Erbe, 2017). Much less is known about the influence of those polymorphisms on the response to CPI and especially PD1 inhibitors. Very recently, a Japanese team reported the association of some polymorphisms of PD1 gene and the response to nivolumab in 50 non squamous cell lung carcinoma patients (Nomizo, 2017). To our knowledge, no data have been yet reported on Caucasian HNSCC patients.
Dr Esma SAADA-BOUZID
HNSCC cancer
intérêt public
Centre Antoine Lacassagne
30 ans